This Biotech Startup Wants to Delay Menopause by 15 Years

Menopause begins when someone’s ovaries produce far less estrogen and progesterone than they once did. This causes said ovaries to slow the release of follicles that influence one’s ability to reproduce. Though everyone hits menopause at a bit of a different pace, Beim believes she and her firm can offset the beginning of this phase by 10 to 15 years, pushing the average onset age up to 70 years old. This would both extend a patient’s fertility and hinder the health issues that coincide with the beginning of menopause, like heart disease, bone disease, and Alzheimer’s.

“If we could buy women an extra 10 to 15 years of natural endocrine function, we’re talking about a huge boost in their vitality and their wellness at a critical stage in their life,” Beim told Fortune when Celmatix’s mission became public last year. Celmatix plans on starting clinical trials of its menopause-delaying drug in 2023. The trials will begin with women undergoing chemotherapy, which is a common cause of premature menopause.

Celmatix’s drug primarily works by mimicking anti-Mullerian hormone (AMH), which ovarian follicles naturally produce to regulate the body’s reproductive functions. Patients will be able to stop taking the drug if they wish to have a baby, just like they already do with birth control. Celmatix is also working under a grant from the Bill and Melinda Gates Foundation to experiment with new non-hormonal birth control, as hormonal options come with a slew of side effects that make most contraceptives unappealing.

Healthcare options largely impacting women have long been under-researched and under-funded for reasons we won’t go into here, but Beim sees big change on the horizon. Since 2020 Celmatix has been working with multinational pharmaceutical and life sciences company Bayer, which has sunk hundreds of millions of dollars into women’s healthcare research in recent years. An increase in awareness of women’s health issues, along with the growth of “femtech” (medical technology focused on those assigned female at birth) are also helping medical professionals take their patients’ experiences more seriously.

Continue reading

Scientists Confirm the Presence of Water on the Moon

Scientists have confirmed the discovery of molecular water on the moon. Is there any of it in a form we can use? That's less clear.

Review: The Oculus Quest 2 Could Be the Tipping Point for VR Mass Adoption

The Oculus Quest 2 is now available, and it's an improvement over the original in every way that matters. And yet, it's $100 less expensive than the last release. Having spent some time with the Quest 2, I believe we might look back on it as the headset that finally made VR accessible to mainstream consumers.

SpaceX Launches ‘Better Than Nothing’ Starlink Beta

Those lucky few who have gotten invitations to try the service will have to pay a hefty up-front cost, and the speeds aren't amazing. Still, it's a new generation of satellite internet.

Samsung, Stanford Built a 10,000 PPI Display That Could Revolutionize VR, AR

Ask anyone who has spent more than a few minutes inside a VR headset, and they'll mention the screen door effect. This could eliminate it for good.